Trending
Inside the uphill battle of getting Google Ads approved for a CLIA-waived, FDA-cleared business.
It started like any normal campaign launch.
Audience? Defined.
Keywords? Tight and compliant.
Ad copy? Approved by lawyers and scrubbed cleaner than an FDA lab bench.
And yet — Google Ads immediately flagged it.
Our campaign for DrugScreens.com, a national distributor of CLIA-waived, FDA-cleared toxicology kits, was shut down before a single impression. The reason?
“Unapproved substances.” “Prescription opioid painkillers.”
Let’s be clear: we don’t sell drugs. We screen for them — for employers, clinics, recovery programs, and government agencies working to keep people safe and compliant.
But the world’s largest advertising platform couldn’t tell the difference.
The never-ending circle
We’ve gone round and round with Google for nearly a month now. Different teams. Different tickets. Different “specialists.”
Every time we ask for clarity, we get routed somewhere new — and every time we end up in the same place: disapproved.
No one can explain the specific issue, offer a fix, or even acknowledge that our products are federally cleared and legally distributed across the U.S.
It’s a digital hamster wheel: full of motion, zero progress.
The irony of “unapproved substances”
The disapproval wasn’t about content or intent — it was about keywords. Specifically, the presence of one: fentanyl.
Google’s policy team asked us to remove all mentions of “fentanyl” from our website if we wanted to advertise.
That’s right — the very substance our clients are required by law to screen for, and that our FDA-cleared test kits detect, cannot even be mentioned.
We’re not promoting drugs. We’re providing tools to keep them out of workplaces, schools, and treatment centers. Yet, the algorithm lumps us into the same category as illegal online pharmacies and counterfeit pill pushers.
The scale of the market — and the absurdity of the block
This isn’t a niche product. The global drug screening market is projected to reach $52 billion by 2023, driven by stricter workplace compliance requirements and a rise in substance misuse post-COVID.
These are serious, regulated industries — staffing firms, transportation companies, government agencies, healthcare networks — all depending on accurate, compliant screening tools.
And yet, legitimate providers like us can’t reach them through standard digital advertising because the automated systems guarding “safety” lack the nuance to understand context.
Automation without accountability
Google’s AI-driven ad moderation is meant to protect users from harm — a good goal in theory. But when automation replaces discernment, the result is collateral damage.
No real escalation path. Just a policy link and an “Appeal” button that leads into a black box.
In a sense, the system itself fails the very compliance and clarity it demands from others.
“Just get LegitScript certified,” they say
Yes, we’re aware of LegitScript. It’s the certification Google recognizes for online pharmacies, telehealth, and drug-related advertising.
But here’s the rub:
- The certification costs thousands of dollars per year.
- It doesn’t guarantee ad approval or payment acceptance.
- And it was primarily built for companies dispensing controlled substances, not for businesses that detect them.
So we’re left in a strange limbo — too compliant for bad actors, too “risky” for Google’s algorithm.
For small businesses selling legitimate, FDA-cleared diagnostic kits, that’s not a workable solution.
The bigger question
If a CLIA-waived, FDA-cleared company selling legal, over-the-counter test kits to government agencies can’t advertise because of a misunderstood keyword, what does that say about the broader digital advertising ecosystem?
Where’s the line between safety enforcement and censorship by algorithm? And how can health, wellness, and diagnostic companies reach the people who need them without getting trapped by misapplied policies?
A call for collaboration
I’m not interested in venting. I’m interested in solving this.
If you’ve navigated this before — whether you’re in healthcare marketing, AdTech, or compliance — I’d love your perspective.
There has to be a better path for legitimate businesses to promote legal, life-saving tools without being penalized by blanket rules.
Because if Google truly wants to make the internet safer, it needs to recognize one simple truth: There’s a difference between a dealer and a detector.
Related: The Untold Story of How America’s Savviest Investors Build Wealth — And Cut Taxes — With Energy